John H Griffin Selected Research

John H Griffin Research Topics

Disease

28	Hemorrhage 01/2021 - 04/2003
26	Ischemic Stroke 01/2022 - 09/2002
26	Thrombosis (Thrombus) 01/2021 - 06/2002
22	Stroke (Strokes) 01/2022 - 07/2002
20	Inflammation (Inflammations) 01/2021 - 02/2003
17	Venous Thrombosis (Deep-Vein Thrombosis) 02/2020 - 08/2005
17	Sepsis (Septicemia) 01/2018 - 07/2002
9	Venous Thromboembolism 01/2018 - 03/2007
8	Infarction (Infarctions) 01/2022 - 04/2003
8	Ischemia 01/2022 - 06/2003
7	Endotoxemia 11/2015 - 10/2007
6	Reperfusion Injury 01/2021 - 02/2006
4	Hemophilia A (Haemophilia) 01/2021 - 03/2016
4	Pulmonary Embolism 01/2021 - 09/2015
3	Edema (Dropsy) 01/2022 - 04/2003
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 04/2003
3	Wounds and Injuries (Trauma) 01/2022 - 10/2016
3	Infections 01/2021 - 04/2015
3	Pneumonia (Pneumonitis) 01/2018 - 09/2011
3	Lung Injury 01/2018 - 09/2011
3	Intracranial Hemorrhages (Intracranial Hemorrhage) 07/2016 - 11/2006
3	Hypoxia (Hypoxemia) 01/2016 - 04/2003
3	Activated Protein C Resistance (APC Resistance) 11/2015 - 04/2007
3	Embolic Stroke 09/2012 - 09/2005
3	Atherosclerosis 11/2011 - 08/2002
3	Dyslipidemias (Dyslipidemia) 09/2010 - 08/2005
3	Brain Ischemia (Cerebral Ischemia) 11/2008 - 05/2004
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 01/2021
2	Bacterial Pneumonia 05/2020 - 01/2018
2	Brain Injuries (Brain Injury) 01/2019 - 04/2003
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2016 - 11/2009
2	Thromboembolism 04/2013 - 09/2009
2	Purpura Fulminans 04/2012 - 04/2007
1	Lung Neoplasms (Lung Cancer) 10/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Peripheral Arterial Disease 01/2022
1	Choroidal Neovascularization 01/2021
1	Acute Radiation Syndrome 01/2021

Drug/Important Bio-Agent (IBA)

63	Protein CIBA 01/2021 - 06/2002
41	AnticoagulantsIBA 01/2021 - 06/2002
17	Thrombin FDA Link 01/2021 - 08/2002
12	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 03/2003
12	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 09/2005
11	Endothelial Protein C ReceptorIBA 01/2022 - 03/2003
10	Neuroprotective AgentsIBA 01/2022 - 04/2003
9	Protein SIBA 01/2020 - 04/2003
8	PAR-1 ReceptorIBA 12/2018 - 11/2006
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2004
6	Thromboplastin (Tissue Factor)IBA 10/2019 - 09/2009
5	3K3A-APC proteinIBA 01/2022 - 12/2013
5	Myosins (Myosin)IBA 01/2021 - 10/2016
5	Serine Proteases (Serine Protease)IBA 01/2020 - 12/2004
5	LipidsIBA 10/2019 - 03/2004
4	Hemostatics (Antihemorrhagics)IBA 01/2022 - 01/2021
4	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 09/2015
4	Factor VaIBA 11/2020 - 09/2002
4	LipopolysaccharidesIBA 01/2020 - 01/2012
4	Therapeutic UsesIBA 01/2018 - 09/2004
4	HDL LipoproteinsIBA 04/2012 - 08/2005
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 03/2009
3	Protein Isoforms (Isoforms)IBA 01/2021 - 09/2010
3	CytokinesIBA 01/2021 - 03/2018
3	ApolipoproteinsIBA 02/2020 - 08/2005
3	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2020 - 01/2018
3	FibrinIBA 01/2020 - 09/2009
3	CoagulantsIBA 01/2020 - 09/2005
3	ThrombomodulinIBA 01/2019 - 01/2006
3	Blood Coagulation Factors (Coagulation Factor)IBA 01/2018 - 04/2015
3	factor V LeidenIBA 11/2015 - 04/2007
2	FIIaIBA 01/2021 - 11/2020
2	InterferonsIBA 01/2021 - 04/2015
2	NF-kappa B (NF-kB)IBA 01/2021 - 11/2006
2	Cardiac MyosinsIBA 01/2021 - 01/2021
2	InflammasomesIBA 01/2021 - 12/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2020
2	AntigensIBA 01/2020 - 09/2002
2	Factor V (Coagulation Factor V)IBA 01/2016 - 04/2012
2	Biological ProductsIBA 11/2015 - 11/2014
2	Biomarkers (Surrogate Marker)IBA 09/2015 - 08/2008
2	Pharmaceutical PreparationsIBA 11/2014 - 01/2012
2	Blood Proteins (Serum Proteins)IBA 08/2013 - 05/2004
2	EndotoxinsIBA 04/2013 - 06/2009
2	oxidized low density lipoproteinIBA 09/2010 - 08/2005
2	EnzymesIBA 05/2007 - 09/2004
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 03/2007 - 08/2005
1	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Factor IIaIBA 01/2021
1	recombinant FVIIa (rFVIIa)FDA Link 01/2021
1	InterleukinsIBA 01/2021
1	AntithrombinsIBA 01/2021
1	Heparin (Liquaemin)FDA LinkGeneric 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021

Therapy/Procedure

30	Therapeutics 01/2021 - 07/2002
3	Thrombectomy 01/2021 - 01/2018
3	Thrombolytic Therapy 02/2011 - 09/2005
1	Radiotherapy 10/2022
1	Ligation 01/2021